Heparan sulfation-dependent fibroblast growth factor signaling maintains embryonic stem cells primed for differentiation in a heterogeneous state

Stem Cells
Fredrik LannerFilip Farnebo

Abstract

Embryonic stem (ES) cells continuously decide whether to maintain pluripotency or differentiate. While exogenous leukemia inhibitory factor and BMP4 perpetuate a pluripotent state, less is known about the factors initiating differentiation. We show that heparan sulfate (HS) proteoglycans are critical coreceptors for signals inducing ES cell differentiation. Genetic targeting of NDST1 and NDST2, two enzymes required for N-sulfation of proteoglycans, blocked differentiation. This phenotype was rescued by HS presented in trans or by soluble heparin. NaClO(3) (-), which reduces sulfation of proteoglycans, potently blocked differentiation of wild-type cells. Mechanistically, N-sulfation was identified to be critical for functional autocrine fibroblast growth factor 4 (FGF4) signaling. Microarray analysis identified the pluripotency maintaining transcription factors Nanog, KLF2/4/8, Tbx3, and Tcf3 to be negatively regulated, whereas markers of differentiation such as Gbx2, Dnmt3b, FGF5, and Brachyury were induced by sulfation-dependent FGF receptor (FGFR) signaling. We show that several of these genes are heterogeneously expressed in ES cells, and that targeting of heparan sulfation or FGFR-signaling facilitated a homogenous Nanog/KL...Continue Reading

References

Jul 15, 1988·Biochemical and Biophysical Research Communications·D E Humphries, J E Silbert
Dec 15, 1986·Biochemical and Biophysical Research Communications·P A Baeuerle, W B Huttner
Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G R Martin
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·F A Brook, R L Gardner
Dec 14, 1999·The Journal of Biological Chemistry·F SafaiyanM Salmivirta
Jun 29, 2000·Annual Review of Biochemistry·M BernfieldM Zako
Mar 9, 2002·Molecular and Cellular Biology·Detlev BiniszkiewiczRudolf Jaenisch
Sep 25, 2003·Cell·María J García-García, Kathryn V Anderson
Dec 31, 2003·Methods in Enzymology·Qi-Long Ying, Austin G Smith
Jun 11, 2004·Annual Review of Biochemistry·Robert S Haltiwanger, John B Lowe
Mar 17, 2005·The Biochemical Journal·Johan KreugerUlf Lindahl
Oct 21, 2005·Development·Dominique StickensZena Werb
Feb 28, 2006·Nature Clinical Practice. Cardiovascular Medicine·Atsushi SuzukiJuan Carlos Izpisúa Belmonte
May 9, 2006·Developmental Cell·Lars JakobssonLena Claesson-Welsh
Jun 13, 2006·Nature·Natalia IvanovaIhor R Lemischka
Dec 23, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Fredrik LannerFilip Farnebo
Nov 21, 2007·The Journal of Biological Chemistry·Norihiko SasakiShoko Nishihara
Dec 22, 2007·Nature·Ian ChambersAustin Smith
Feb 12, 2008·Nature Cell Biology·Jianming JiangHuck-Hui Ng
Feb 26, 2008·Cell·Jose Silva, Austin Smith
Mar 1, 2008·Journal of Theoretical Biology·Albert Goldbeter, Olivier Pourquié
May 24, 2008·Nature·Qi-Long YingAustin Smith
Sep 26, 2008·Gene Expression Patterns : GEP·Ryutaro Hirasawa, Hiroyuki Sasaki
Oct 8, 2008·Genesis : the Journal of Genetics and Development·Laura Batlle-MoreraJennifer Nichols

❮ Previous
Next ❯

Citations

Jan 5, 2012·Proceedings of the National Academy of Sciences of the United States of America·Laralynne M Przybyla, Joel Voldman
Dec 15, 2010·The Journal of Biological Chemistry·Rebecca J HolleyCatherine L R Merry
Feb 3, 2012·The Journal of Biological Chemistry·Maud ForsbergKarin Forsberg-Nilsson
Dec 25, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yi-Chin Toh, Joel Voldman
Jun 22, 2011·Cold Spring Harbor Perspectives in Biology·Stephane SarrazinJeffrey D Esko
Oct 9, 2012·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Christoffer TammJin-Ping Li
Feb 2, 2013·Biological Chemistry·Daniel C KraushaarLianchun Wang
Apr 25, 2012·Annual Review of Analytical Chemistry·Laralynne Przybyla, Joel Voldman
May 6, 2014·Cellular and Molecular Life Sciences : CMLS·Jérôme Artus, Claire Chazaud
Jan 23, 2016·Stem Cells International·Luca FagnocchiAlessio Zippo
Feb 11, 2011·Stem Cells·Claire E PickfordCatherine L R Merry
Oct 10, 2013·Molecular Systems Biology·Silvia Muñoz DescalzoAlfonso Martinez Arias
Jun 1, 2013·Biomolecular Concepts·Vimal P SwarupBalagurunathan Kuberan
Dec 18, 2020·Frontiers in Cell and Developmental Biology·Maanasa RavikumarSimon M Cool
Oct 12, 2021·Frontiers in Cell and Developmental Biology·Chika Ogura, Shoko Nishihara
Feb 14, 2013·Stem Cells·Laralynne M PrzybylaJoel Voldman
Jul 23, 2011·Nature Chemistry·Morgan D MagerMolly M Stevens
Oct 11, 2011·Current Opinion in Cell Biology·Alfonso Martinez Arias, Joshua M Brickman
Mar 5, 2020·Computational and Structural Biotechnology Journal·Xin Kang, Chunhe Li
Dec 8, 2011·Development·Katsuyoshi Takaoka, Hiroshi Hamada
Mar 20, 2012·Developmental Cell·Peter J Rugg-GunnThomas Kislinger
May 5, 2012·The Journal of Biological Chemistry·Daniel C KraushaarLianchun Wang
Dec 4, 2012·Current Opinion in Genetics & Development·Jordi Garcia-Ojalvo, Alfonso Martinez Arias

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.